Drug Profile
Research programme: GP41 inhibitors - Locus Pharmaceuticals
Alternative Names: GP41 inhibitors research programme - Locus PharmaceuticalsLatest Information Update: 21 Jan 2010
Price :
$50
*
At a glance
- Originator Locus Pharmaceuticals
- Class Small molecules
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Viral infections
Most Recent Events
- 22 Jun 2005 This programme is still in active development - (BIO-2005)
- 22 Jun 2004 The gp41 fusion inhibitors programme is available for licensing (http://www.locuspharma.com)
- 27 Feb 2003 Preclinical trials in Viral infections in USA (PO)